In a high-profile patent invalidation case concerning an anticancer drug crystal patent, the Patent Reexamination and Invalidation Examination Department of the China National Intellectual Property Administration (CNIPA) issued its latest decision on the request for invalidation, once again sustaining the validity of the crystal patent.

Liu Shen represented the patentee in the proceeding. The case was jointly handled by Partners Stephen ZOU, CAO Lili and XU Feifei, together with Lawyers JIA Zhaonian and ZHU Wenjing. Through in-depth communication with the client and thorough case preparation, the team delivered a robust response to the unilateral experimental data submitted by the petitioner for patent invalidation.

The panel adopted the arguments presented by the Liu Shen team and ruled to maintain the validity of the crystal patent. This marks the third time the Liu Shen team has secured a favorable ruling for the patent at the patent invalidation stage.

In this representation, Liu Shen’s biopharmaceutical practice team delivered exceptional professional services by virtue of its profound technical expertise, precise interpretation of patent claims, and extensive experience in patent invalidation matters. The result once again demonstrates the firm’s rigorous professional standards and unwavering pursuit of excellence.